Ogerin is primarily researched for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a selective negative allosteric modulator of the GPR3 receptor, which is implicated in the regulation of amyloid-beta production. By modulating this receptor, Ogerin may help reduce amyloid-beta accumulation, a key pathological feature of Alzheimer's. Additionally, its neuroprotective properties are being explored for their ability to mitigate cognitive decline and improve memory functions in preclinical models. Researchers are also investigating its potential in other conditions involving GPR3 receptor dysregulation.